Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Gemcitabine

Imatinib Mesylate

Antimetabolites

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

All research subjects receive oral imatinib 400mg days 1-5 and 8-12 of a 21 day cycle.

All research subjects received IV gemcitabine 1000mg/m2 days 3 and 10 of a 21-day cycle. .

All subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis and had failed to respond to prior chemotherapy or progressed after prior chemotherapy.

imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.

imatinib mesylate by mouth

Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle

Gemcitabine Intravenous

David McCune, MD, MPH

This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy drug used. Participation in the treatment portion of the study will continue as long as the patient's tumors shrink or remain stable and as long as the patient is able to tolerate the study drug. The follow-up portion of the study will last for 5 years.

Each 21 day period will be considered a cycle. Disease status will be assessed with a Cancer Antigen (CA)-125 prior to the start of each new cycle with an assessment of measurable diseased by either CT or MRI every 6 weeks. Treatment will continue until disease progression, unacceptable toxicities, or the patient elects to withdraw from the study. All patients will be followed until disease progression or study withdraw. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years, unless consent is withdrawn.

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

A Phase II Trial of Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer Who Have Failed at Least Two Prior Therapies

Progression free survival at six months was assessed for all research subjects. Progression defined by SWOG criteria: Invest New Drugs. 1992 Nov;10(4):239-53. Progression is defined as \> 50% increase in the sume of measured cross sectional area of areasa of measurable disease, measured from the lowest measured amount of disease. Progression is also defined as new areas of measurabe disease.

Toxicity was assess prior to each cycle of therapy (every 3 weeks) and graded based on NCI common toxicity criteria

Best response to thearpy was assessed using modified SWOG criteria (same as for outcome masure #1). Subjects were assess as "complete response", "partial response", "stable disease", and "progressive disease" after 2 cycles (6 weeks) of beginning treatment and every 6 weeks afterward until progression of disease, unacceptable toxicity, or subject withdrawl from study.

the measurement reported is the number of patients who met the criteria for partial response.

All subjects were followed after treatment was complete to assess overall survival.

Using SWOG criteria for response of measurable disease, subject best response was assessed. First assessment was 6 weeks after starting treatment. Subjequent evaluations were every 6 weeks in patients who remained on study.

Repsonse rate was the sum of Complete Repsonse and Partial Response.

The study was stopped after 8 subjects. It was not possible to perform meaningful analysis on prognostic variables. this outcome measure was not done.

Novartis

Henry M. Jackson Foundation for the Advancement of Military Medicine

Principal Investigator

Adverse events were scored based on NCI common toxicity criteria. All serious adverse events and all non-serious adverse events were reported.

Open label, non-randomized, single treatment group.

Treatment

Age, Categorical

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

This study was terminated due to a combination of poor accrual and lack of evidence of benefit.

COL David E. McCune, MD, MC

Open label, non-randomized, single treatment group.

All subjects has measurable or evaluabel epithelial ovarian cancer or preitoneal carcinomatosis. all subjects were treated with oral imatinib and IV gemcitabine.

Oral Imatinib Plus Gemcitabine

of 8 enrolled subjects, 7 were eligible for analysis of progression-free survival at 8 months. One subject declined to continue treatment

The Cystostatic, Anti-tumor Activity of the Combination of Gleevec and Gemzar Via Progression-free Survival for at Least Six Months in Patients With Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma.

Grade 3 toxicity

Grade 4 toxicity

Red Blood Cell Transfusion

Oral Imatinib Puls IV Gemcitabine

To Determine the Safety and Tolerability Via Frequency and Severity of Adverse Effect of Combination Gleevec and Gemzar in This Cohort of Patients as Assessed Byt Common Toxicity Criteria

Open label, non-randomized, single treatment group. all subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis that progressed after prior treatment.

Oral Imatinib Plus IV Gemcitabine

All subjects who underwent treatment and participated in the study were analysed

Tumor Response Rates Using Modified SWOG Criteria to the Combination of Gleevec and Gemzar in Patients With Relapsed Ovarian Cancer Who Have Failed at Least One Prior Chemotherapy Treatment.

To Determine the Distribution of the Overall Survival

All subjects were assessed after 6 weeks of treatment and reassessed at 6 week intervals

To Estimate the Clinical Response Rate(Partial and Complete Response as Defined Under the SWOG Criterial)

To Assess the Effects of Prognostic Variables; Initial Performance Status; Platinum Sensitivity, and Mucinous (or Clear Cell)Histology on Progression-free Survival Overall.

Overall Study

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Adenocarcinoma, Bronchiolo-Alveolar

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Alpha 1-Antitrypsin

Protein C Inhibitor

- Examples include invasive mucinous/non-mucinous non-small cell lung cancers and multifocal carcinomas

- Examples include germ cell tumors, head \& neck tumors, colorectal tumors, renal cell tumors

- Examples include, but not limited to interstitial lung disease (ILD), pulmonary fibrosis (idiopathic or secondary), advanced chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and pulmonary arterial hypertension (PAH)

To evaluate outcomes among patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.

Double Lung Transplantation

Lung Transplant Thoracic Surgery, Canning Thoracic Institute (Northwestern Memorial Hospital)

Liam Il-Young Chung, MD MPH

Young Chae, MD MPH MBA

Ankit Bharat, MD

Rade Tomic, MD

This is a prospective observational registration trial for patients who undergo lung transplantation for the treatment of the select groups of medically refractory cancers affecting the lungs alone without extrapulmonary nodal and distant metastasis.

Ever since human lung transplantation was first performed in a patient with advanced lung cancer in 1963 \[1\], it has emerged as a well-established treatment for patients suffering from a variety of end-stage pulmonary diseases. While lung transplant continues to be performed for refractory lung-limited malignancies that do not have extrapulmonary disease \[2-6\], given the perceived risks of tumor recurrence following transplantation and potentially reduced survival compared to patients with chronic end-stage lung diseases, transplants for cancer constitutes less than 0.5% of all such procedures (www.srtr.org). The need for lung transplantation is not only confined to patients with primary lung cancers. There are unmet needs for patients who have lung-limited metastasis after successful treatment for primary tumors such as sarcomas or colorectal cancer (CRC). Indeed, successful reports of lung transplantation for lung only metastasis that are refractory to standard of care treatment has been demonstrated \[3\] and proposed by international experts in highly selected patients \[6\]. Solid organ transplantation for both primary and metastatic cancers has been demonstrated in liver transplantation \[7, 8\]. While uncommonly performed, for patients with refractory lung cancer or those with concomitant respiratory failure, lung transplantation may be the only treatment option. The 5-year overall survival of patients in some prior reports who underwent double lung transplantation (DLT) for lung cancer was 39-57%\[2, 9\], compared to those with non-malignant diseases 50-59%\[10, 11\]. Indeed, lung transplants have been steadily increasing for cancers, as evident in the International Society of Lung Transplantation (ISHLT) \[4-6\]. However, the reported cases represent heterogeneity in the surgical technique, patient selection, and post-operative management.

This prospective observational registry aims to better understand the long-term outcomes in patients undergoing double lung transplantation for lung-limited cancers in the clinical programs at Northwestern Medicine and participating centers. We aim to study the impact of a standardized approach to patient selection, tumor staging, surgical technique, and post-operative management on the long-term survival following lung transplantation in patients with lung-limited malignancy. Specifically, this study aims to investigate the clinical outcomes of patients who undergo lung transplantation for treatment of a select group of medically refractory cancers affecting the lungs without extrapulmonary metastases. Patients will undergo transplantation if they have failed standard of care treatments and do not have further curative treatment/trials options. Their clinical courses including overall survival, disease-free survival, and graft failure will be monitored as well as the molecular and genetic biomarkers to investigate the correlation with the prognosis.

DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies

Double Lung Transplant REgistry Aimed for Lung-limited Malignancies (DREAM) - a Prospective Observational Registry Study for Patients Undergoing Lung Transplantation for Medically Refractory Cancers Confined to the Lungs

including acute kidney failure requiring continuous renal replacement therapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer	NCT00928642	Ovarian Cancer Primary Periton...	imatinib mesyla... Gemcitabine Int...	18 Years -	Henry M. Jackson Foundation for the Advancement of Military Medicine
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer	NCT00928642	Ovarian Cancer Primary Periton...	imatinib mesyla... Gemcitabine Int...	18 Years -	Henry M. Jackson Foundation for the Advancement of Military Medicine
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies	NCT05671887	Lung Cancer Bilateral Cance... Lung Transplant	Double Lung Tra...	18 Years - 75 Years	Northwestern University

Spots Global Cancer Trial Database for mucinous

Every month we try and update this database with for mucinous cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for mucinous

Every month we try and update this database with for mucinous cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for mucinous cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.